palonosetron sold brand name aloxi used prevention treatment chemotherapyinduced nausea vomiting palonosetron administered single oral longer duration action antagonists oral formulation approved august prevention acute cinv alone large clinical trial show oral administration effective intravenous use delayed world health organizations list essential oral combination netupitantpalonosetron approved acute delayed common adverse effects headache occurs patients constipation patients less patients gastrointestinal disorders occur well sleeplessness first seconddegree atrioventricular block muscle pain shortness breath palonosetron similarly well tolerated antagonists slightly less palonosetron relevantly inhibit induce cytochrome liver enzymes case reports serotonin syndrome drug combined serotonergic substances selective serotonin reuptake inhibitors ssris reuptake inhibitors snris two common types palonosetron antagonist commonly known setron drugs act blocking serotonin binding orally taken palonosetron absorbed well gut bioavailability highest blood plasma levels reached hours independently food intake plasma protein binding substance eliminated unchanged form metabolized liver enzyme lesser extent two main metabolites noxide hydroxy derivative less palonosetrons antagonistic effect thus practically palonosetron metabolites mainly eliminated via kidney biological halflife healthy persons hours study hours cancer patients patients halflife marketed setrons halflives range two hours substance solid room temperature melts infusions capsules contain palonosetron also solid hydrochloride easily soluble water soluble propylene glycol slightly soluble ethanol isopropyl molecule two asymmetric carbon atoms used form pure palonosetron developed helsinn around january helsinn filed provisional patent application palonosetron next years helsinn filed four patent applications claimed priority january date relevant helsinn filed fourth patent application patent patent covers fixed dose mg palonosetron ml solution developing drug helsinn entered confidential licensing agreement company called mgi sell palonosetron united states licensing agreement contained chemical information palonosetron dosage requirements however helsinn file patent palonosetron two years signed agreement mgi teva pharmaceuticals generic drug manufacturer challenged validity helsinns patents filing application generic version palonosetron fda teva claimed helsinn disclosedsold mg dose palonosetron mgi year actually years priority date patent secret sale barred helsinn received patent conclusion results language america invents act bars patents inventions public use sale otherwise available public effective filing date claimed invention u c district court held aias sale provision apply public disclosure agreements disclose mg dose federal circuit reversed holding sale publicly disclosed regardless whether details invention publicly disclosed terms sale agreements scotus agreed federal circuit case commercial sale third party required keep invention confidential nevertheless placed invention sale usc helsinn healthcare v teva pharmaceuticals usa inc httpsenwikipediaorgwikipalonosetron